BOARD OF DIRECTORS

ANDREW ALBERT “AL” KUCHARCHUK

Andrew Kucharchuk joins CERo from Nukkelous, Inc. and Chain Bridge I, Inc., both Nasdaq-traded companies where he served as Chief Financial Officer.  Previously, he served in C-suite positions and/or as a board member at publicly traded life sciences companies Theralink (CFO, Board member), Adhera Therapeutics (Board member, multiple C-suite positions), and OncBioMune (CEO, CFO, President).  He holds a Master of Business Administration from Tulane University and a Bachelor of Science degree in agricultural business/finance from Louisiana State University.

Jed Latkin

Jed Latkin has nearly three decades of experience with financial and biotech companies. Jed’s experience includes serving as the Chief Operating Officer and head of Finance for ProPhase Labs, Inc. since January 2023, and as the Chief Executive Officer of Navidea Biopharmaceuticals, Inc., where he raised over $160 million and arranged a key transaction for Navidea that resulted in consideration up to $310 million. While at Navidea, he also served as the Chief Financial Officer prior to becoming the Chief Executive Officer. In connection with his role at Nagel Avenue Capital, he also served as Chief Executive Officer of Black Elk Energy Offshore in 2014. Jed started his career by spending ten years on Wall Street with a variety of investment banking organizations and funds including ING, Morgan Stanley and Citigroup Securities.

Saundra Pelletier​

Saundra Pelletier has served as the Interim Chair since late 2021 and as Chief Executive Officer, President and Executive Director since early 2015 of Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company focused on commercializing innovative products to address unmet needs in women’s health. Ms. Pelletier brings more than twenty-five years of broad executive leadership experience to Windtree’s board, including successes in driving multiple, billion-dollar product launches, expanding organizational capabilities in ex-U.S. markets and advocating for women’s health. Throughout her career, she has had oversight and accountability for nearly all aspects of commercialization, manufacturing and medical and business development. Saundra has also served on the board of directors for TRACON Pharmaceuticals, Inc., since early 2020, which is focused on developing novel oncology therapeutics.

Dr. Mark Strobeck

Dr. Strobeck has more than 20 years of experience in operations, business development, capital raising and M&A and has a track record of success creating and building value for emerging and public biotechnology and life sciences companies. Currently, Dr. Strobeck is President and CEO, and a Member of the Board, at Rockwell Medical, a publicly held healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.

Prior to joining Rockwell in 2022, Dr. Strobeck held positions at investment banking and pharmaceutical companies including Aquilo Partners, Zyla Lifesciences (acquired by Assertio Therapeutics), Corridor Pharmaceuticals (acquired by AstraZeneca), and Topaz Pharmaceuticals (acquired by Sanofi Pasteur).

Dr. Strobeck completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania, earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, and earned his bachelor’s degree in biology from St. Lawrence University.